KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: Evaluation of a strip-based reverse-hybridisation assay

Journal of Clinical Pathology

Volumn 64, Issue 3, 2011, Pages 252-256

  Kriegshäuser, Gernot ^a   Auner, Veronika ^b   Schuster, Eva ^c   Holzer, Barbara ^c   Oberkanins, Christian ^a   Horvat, Reinhard ^d   Speiser, Paul ^c   Zeillinger, Robert ^b,c  

^a VIENNALAB DIAGNOSTICS GMBH   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; GENOMIC DNA; PARAFFIN;

ARTICLE; BIOCHIP; CODON; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HYBRIDIZATION; MUTATIONAL ANALYSIS; OLIGONUCLEOTIDE PROBE; ONCOGENE K RAS; OVARY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE HYBRIDIZATION ASSAY; SENSITIVITY AND SPECIFICITY; TEST STRIP; TISSUE SECTION;

DNA, NEOPLASM; FEMALE; FORMALDEHYDE; HUMANS; MUTATION; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAGENT STRIPS; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION;

EID: 79951949395     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.081414     Document Type: Article

References (22)

1. Aunoble B, Sanches R, Didier E, et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol 2000;16:567-76.
2. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
3. Caduff RF, Svoboda-Newman SM, Ferguson AW, et al. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999;23:323-8. (Pubitemid 29117569)
4. Fabjani G, Kriegshaeuser G, Schuetz A, et al. Biochip for K-ras mutation screening in ovarian cancer. Clin Chem 2005;51:784-7. (Pubitemid 40463933)
5. Mayr D, Hirschmann A, Lohrs U, et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006;103:883-7. (Pubitemid 44821309)
6. Auner V, Kriegshäuser G, Tong D, et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009;9:111.
7. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9. (Pubitemid 351171687)
8. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7. (Pubitemid 47325606)
9. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
10. van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 2007;18:99-103. (Pubitemid 46152507)
11. Palayekar MJ, Herzog TJ. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer 2008;18:879-90.
12. Mustea A, Sehouli J, Fabjani G, et al. Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. Anticancer Res 2007;27:1527-30. (Pubitemid 46807232)
13. Ausch C, Buxhofer-Ausch V, Oberkanins C, et al. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 2009;11:508-13.
14. Fabjani G, Kucera E, Schuster E, et al. Genetic alterations in endometrial hyperplasia and cancer. Cancer Lett 2002;175:205-11. (Pubitemid 34001719)
15. Schuetz AJ, Prix L, Giesing M, et al. A novel nanopipetting solution for the development of high quality biochip arrays for diagnostic applications. J Assoc Lab Autom 2000;5:72-4.
16. Prix L, Uciechowski P, Bockmann B, et al. Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. Clin Chem 2002;48:428-35. (Pubitemid 34174576)
17. Edkins S, O'Meara S, Parker A, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006;5:928-32.
18. Keohavong P, DeMichele MA, Melacrinos AC, et al. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996;2:411-18. (Pubitemid 26074623)
19. Lilleberg SL, Durocher J, Sanders C, et al. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann N Y Acad Sci 2004;1022:250-6. (Pubitemid 38951611)
20. Do H, Krypuy M, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
21. Kotoula V, Charalambous E, Biesmans B, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 2009;4:e7746.
22. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005;7:413-21. (Pubitemid 41149657)